{"filing":{"accession_number":"0001193125-26-265858","cik":"0001842295","ticker":"MAZE","company_name":"Maze Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-10","report_date":null,"primary_document":"d110541d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1842295/000119312526265858/d110541d8k.htm"},"events":[{"id":5661,"run_id":4963,"accession_number":"0001193125-26-265858","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst \u0026 Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.","company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","filing_date":"2026-06-10","form":"8-K","submitted_at":null,"items":[{"id":5866,"accession_number":"0001193125-26-265858","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst \u0026 Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:29.902895+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5866,"accession_number":"0001193125-26-265858","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Maze Therapeutics' 2026 annual meeting held on June 8, 2026. The filing reports voting outcomes for two proposals: election of directors Jason Coloma and Neil Kumar (both elected), and ratification of Ernst \u0026 Young LLP as independent auditor (ratified with overwhelming support). The detailed vote tallies and quorum confirmation are hallmarks of shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-10T20:17:29.902895+00:00","company_name":"Maze Therapeutics, Inc.","ticker":"MAZE","filing_date":"2026-06-10"}]}